UNSPSC 51101651: Diclazuril

This classification denotes an antiprotozoal agent with the molecular formula C17H9Cl3N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K110K1B1VE, chemically known as r64,433 but generally known as diclazuril, which bears US NIH Compound Identifier 58902. European Medicines Agency schedules Diclazuril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07091MIG. The term DICLAZURIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27).

Most nations schedule diclazuril under HS 29336980 and SITC 51576. As of Q4 2014, DICLAZURIL remains the US FDA Preferred Term for this commodity. Diclazuril bears US NLM identifiers UMLS ID C0057874 and NCI Concept Code C76418. SMILES: CLC1C(C(C2CCC(CL)CC2)C#N)C(CL)CCC1N1NCC(=O)[NH]C1=O.

UNSPSC 51101651 Diclazuril, a Commodity code, ostensibly categorizes a specific antiparasitic medication, but recent state and local solicitations tagged with this code show no actual procurement of diclazuril itself; instead, agencies are buying naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products, and medical supplies for emergency response, indicating a significant mismatch between the code's nominal scope and what is actually being solicited under it. State and local governments buying pharmaceuticals and medical supplies through this code include county health departments, state health and human services commissions, municipal fire departments, and cooperative purchasing alliances serving multiple jurisdictions. The work ranges from direct procurement of emergency pharmaceutical inventories (naloxone, drug deactivation systems) to establishing framework agreements for generic medications and OTC products distributed through authorized wholesalers, and acquisition of medical and first aid supplies for emergency response operations.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Seminole County, Florida issued an IFB on June 30, 2026 (due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries. The Texas Health and Human Services Commission released an RFI on April 3, 2026 to explore direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The City of Tampa's Purchasing Department solicited sealed bids (due March 13, 2026) for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, with an estimated contract value of $700,000.00 and a sheltered small local business enterprise set-aside offering a 5 percent bid discount not to exceed $10,000. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson wholesalers, effective July 1, 2026. The code shows little activity aligned to its actual pharmaceutical commodity classification; the opportunities present indicate taggging errors rather than genuine diclazuril procurement.